Neuromuscular Diseases and Rehabilitation by Demir, Yasemin Parlak
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Neuromuscular Diseases and Rehabilitation
Yasemin Parlak Demir
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67722
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Yasemin Parlak Demir
Additional information is available at the end of the chapter
Abstract
Neuromuscular diseases (NMDs) are a heterogeneous group of diseases that are inher‐
ited or acquired, resulting from an abnormality in the anterior horn motor cells, periph‐
eral nerves, neuromuscular junctions, or muscles.
In NMDs, evaluation is performed to monitor the progression of the disease, to determine 
the appropriate treatment methods, to investigate the efficacy of treatment methods, and 
to predict and prevent possible complications. Evaluation methods should include evalu‐
ation of respiratory functions, muscle testing, normal joint movement, evaluation of flex‐
ibility, evaluation of motor functions and functional capacities, functional posture, and 
gait analysis.
The aim of physiotherapy approaches is to improve the quality of life of patients and 
their families. The rehabilitation program should include the protection of the functional 
level of the patient and the physical and psychological functions, increasing the physical 
and mental capacity of the patient, and slowing the progress of the disease symptoms. 
The rehabilitation program should include the preservation of muscle strength, an exer‐
cise program for the prevention of contractures, increasing respiratory function and aero‐
bic capacity, gait and balance training, fall prevention, walking aid training, psychosocial 
approach, vocational counseling, ergotherapy processes and nutrition expert support.
Keywords: neuromuscular diseases, physiotherapy, rehabilitation, ICF, assessment
1. Introduction
1.1. Identification and classification of NMD
Neuromuscular diseases (NMDs) are a heterogeneous group of diseases that are inherited or 
acquired, resulting from an abnormality in the anterior horn motor cells, peripheral nerves, 
neuromuscular junctions, or muscles [1]. The most common neuromuscular diseases are 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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motor neuron diseases, neuropathies, neuromuscular junction diseases, and muscular dis‐
eases based on anatomic localization [2].
Motor neuron diseases are a group of diseases that progress with lower and/or upper motor 
neuron involvement in motor neurons in the anterior horn of medulla spinalis. They are char‐
acterized by muscle weakness associated with fasciculation and atrophy that differs with 
respect to the location and function of the affected motor neurons. Hereditary spinal muscular 
atrophy (SMA) is the most common motor neuron disease. SMA is caused by the degenera‐
tion of the anterior horn cells in the spinal cord and brain stem and by the activation of the 
corticospinal tract. Progressive symmetrical weakness, hypotonia, hyporeflexia or areflexia, 
muscle atrophy, fasciculation typically affecting the tongue, and postural tremor in the fin‐
gers are typical signs and symptoms of SMA. Spasticity may also be seen as a disease‐specific 
finding in patients with upper motor neuron involvement such as amyotrophic lateral scle‐
rosis (ALS) [3].
Neuropathies are peripheral nerve diseases with sensory and motor symptoms. The observa‐
tion of sensory changes in addition to muscle weakness distinguishes peripheral nerve dis‐
eases from diseases of other components of the motor unit. It causes demyelination in the 
nerve and axonal degeneration in the nerve by affecting the nerve myelin sheath and/or axon 
[4]. The most common neuropathies are hereditary, but there are also different syndromes 
such as inflammatory, toxic, and infectious neuropathies [2]. The loss of muscular strength 
and muscular atrophy is observed starting from feet and legs in the lower extremity and 
hands in the upper extremity, while paresthesia/dysesthesia is observed in a stocking‐glove 
distribution [5]. The most common Charcot‐Marie‐Tooth (CMT) disease or hereditary motor 
and sensory neuropathy constitutes a genetically heterogeneous group of diseases affect‐
ing the peripheral nervous system. CMT, which is characterized by the abnormal develop‐
ment or degeneration of the peripheral nerve, has different genetic pattern transitions. The 
disease begins during infancy in many cases. Symptoms include inadequate gait, muscular 
atrophy and weakness progressing from the distal to proximal extremities, foot deformities 
such as cavus deformity, deep tendon reflex loss, and sensory loss in the distal extremities. 
Inappropriate gait may be evident as walking with jumping and there may be a prone to fall‐
ing [6–8]. Hereditary neuropathies are diseases affecting peripheral nerves and classified as 
hereditary motor and sensory neuropathies (HMSNs), hereditary motor neuropathies, hered‐
itary sensory neuropathies, and hereditary sensory and autonomic neuropathies. Autonomic 
neuropathies include loss of sweating, bladder dysfunction, constipation, and impotence in 
males [5, 9].
Neuromuscular junction diseases are autoimmune diseases that result from the destruc‐
tion, impairment, or absence of one or more proteins during neuromuscular transmission. 
Most neuromuscular junction diseases are acquired and occur associated with presynaptic, 
synaptic, and postsynaptic disorders. Myasthenia gravis (MG), the result of a postsynap‐
tic disorder, is the most common neuromuscular transmission disorder [10, 11]. MG has 
two clinical forms: ocular and generalized. Weakness in the ocular form is limited to the 
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 eyelids and extraocular muscles. In generalized myasthenic patients, however, there is also 
a weakness in the bulbar, extremity, and respiratory muscles in varying degrees due to the 
cranial involvement. As a result, ptosis, diplopia, dysphagia, and dysarthria are observed. 
Myasthenic weakness typically fluctuates during the day, usually the least in the morning, 
and worsens as the day progresses with prolonged use of muscles, especially those that are 
stiff [12–15].
The main problem in muscle diseases involves the degeneration in muscle rather than in the 
nerve. It is a group of genetic diseases proceeding with progressive muscle weakness that 
causes subsequent limitation of joint movements, shortness of muscles, a decrease in respira‐
tory capacity, and posture disorders. The loss of function in the body and in the upper and 
lower limb, impairment of organization of postural reactions, fatigue, loss of cardiopulmo‐
nary adjustment, and disturbed psychosocial condition are among the clinical and functional 
problems encountered [16, 17]. Different functional levels and clinical characteristics may be 
observed ranging from minimal influence to being confined to bed depending on the type of 
disease, the age of onset, and the location of the affected muscle group (proximal and/or dis‐
tal). Bed confinement is observed in the early period in Duchenne musculoskeletal dystrophy 
(DMD) and Becker muscular dystrophy (BMD). However, facioscapulohumeral musculo‐
skeletal dystrophy (FSHMD) and limb‐girdle muscular dystrophy (LGMD) progress slowly 
and decrease the patient's functional ability and quality of life by causing scoliosis, wing 
scapula, difficulty in going up or down the stairs, toe walking and lordotic posture, difficulty 
in standing up from a sitting or squatting position, and Gower's sign. Gower's sign indicates 
the weakness of the proximal muscles, namely those of the lower limb. The sign describes 
a patient that has to use their hands and arms to “walk” up their own body from a squat‐
ting position due to lack of hip and thigh muscle strength, and contractures are observed 
[18]. In many types of diseases, the decreased pulmonary function is due to the respiratory 
muscle weakness and spinal deformities (kyphoscoliosis), which leads to respiratory tract 
infections and respiratory disorders. Cardiomyopathy and arrhythmia lead to cardiac failure 
and this cardiorespiratory complications cause death [19]. In the literature, various classifi‐
cations were done according to the rate of progression of the disease, the affected area, and 
the body part involved, but the most recent classification was done according to the Belgian 
Neuromuscular Disease Registry [20]. The classification of neuromuscular diseases is given 
in Table 1.
According to the international classification of health, function, and disability (ICF) by the 
World Health Organization (WHO), neuromuscular disorders are associated with disability 
in body structure and function, resulting in problems with activity and participation [21]. 
These problems in muscle diseases can be addressed in two parts: primary and secondary. 
Primary disorders are muscular pain, atrophy, pseudohypertrophy, myotonia, and the loss 
of postural control, while the secondary ones are fatigue, difficulty in transfer activities and 
mobility problems, exercise intolerance, contractures, respiration, and psychological prob‐
lems. The problems observed in the patient are related to the type of disease, pathogenesis, 
and progression of illness [22].
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1. Muscular dystrophies 2. Myotonic and 
relaxation disorders
3. Myopathies 4. Disorder of the 
neuromuscular 
transmission
5. Disorder of the motor 
neurons
6. Neuropathies
1. Congenital muscular 
dystrophy
2. Duchenne muscular 
dystrophy
3. Becker muscular 
dystrophy
4. Dystrophinopathy
5. Facioscapulohumeral 
dystrophy
6. Limb girdle muscular 
dystrophy
7. Emery‐Dreifuss muscular 
dystrophy
8. Distal myopathy
9. Oculopharyngeal 
muscular dystrophy
10. Myotonic dystrophy 
type 1
11. Myotonic dystrophy 
type 2
12. Other muscular 
dystrophies
1. Thomsen‐type 
myotonia congenita
2. Becker‐type myotonia 
congenita
3. Paramyotonia 
congenita
4. Familial periodic 
paralysis
5. Other myotonic 
disorders
a. Congenital myopathies
1. Central core disease
2. Multiminicore disease
3. Nemaline myopathy
4. Myotubular
b. Myopathy
5. Centronuclear myopathy
6. Fiber‐type disproportion 
myopathy
7. Metabolic myopathies
8. Muscle glycogenoses
9. Disorders of fatty acid 
metabolism mitochondrial 
myopathy 
c. Inflammatory 
myopathies
10. Polymyositis
11. Dermatomyositis
12. Inclusion body myositis
13. Other myopathies
1. Myasthenia gravis
2. Congenital 
myasthenia
3. Lambert‐Eaton 
syndrome
4. Other disorders 
of neuromuscular 
transmission
1. Amyotrophic lateral 
sclerosis
2. Primary muscular 
atrophy
3. Postpolio syndrome
4. Primary lateral 
sclerosis
5. Werdnig‐Hoffman 
spinal muscular atrophy
6. Intermediate spinal 
muscular atrophy
7. Kugelberg‐Welander 
spinal muscular atrophy
8. Adult spinal muscular 
atrophy
9. X‐linked bulbo‐spinal 
muscular atrophy or 
Kennedy's disease
10. Distal spinal 
muscular atrophy
11. Hereditary spastic 
paraplegia
12. Other disorders of 
motor neurons
a. Hereditary
1. Hereditary motor and 
sensory neuropathy
2. Hereditary neuropathy 
with liability to pressure 
palsies
3. Hereditary sensory & 
autonomous neuropathy
b. Inflammatory
4. Guillain‐Barré 
syndrome
5. Chronic inflammatory 
demyelinating 
polyneuropathy
6. Multifocal motor 
neuropathy
7. Vasculitis
8. Neuropathy associated 
with paraproteinemia
9. Neuropathy associated 
with plasma cell 
dyscrasia
10. Amyloisdosis
11. Neuropathy in 
systemic disease
12. Other neuropathies
7. Hereditary ataxias and 
others
Table 1. Classification of neuromuscular diseases [20].
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2. Body structure and function disorders in NMD according to the 
international classification of function
2.1. Loss of strength
The progressive loss of strength, severity of which changes depending on the type of the disease, 
is one of the leading problems that constitute the deficiencies seen in neuromuscular diseases. 
The functional deficiencies seen in neuromuscular diseases vary depending on the localization 
of affected muscle groups and secondary outcomes caused by muscle weakness vary depend‐
ing on the type and progression of the disease but it should be remembered that the severity 
of the disease may vary due to the individual differences among the patients [23]. The loss of 
strength can be seen in the distal and/or proximal region. Also, the loss of strength can also be 
seen in the neck and mimic muscles. The reason for the progressive loss of muscle strength in 
neuromuscular diseases varies according to the nature of the disease. It is due to the reduction 
in the number and size of intrinsic contractile fibers in muscle diseases that are followed by 
replacement of these fibers by fat infiltration and connective tissue. These changes are caused 
by the disturbance in the nerve stimulation and transmission pathways necessary for muscle 
contraction [7, 18]. Also, the decrease in the optimal length of the muscle and deterioration of 
the sarcomere structure resulting from decreased physical activity secondary to the disease is 
among the causes of the development of immobilization. It has been shown in the literature 
that the muscle ceasing to the contraction has lost half of its strength after 3–5 weeks [24]. For 
example, patients with FSMD typically show weakness around the shoulder and facial muscles, 
thereby weakening the activities involving the upper extremity for function, while DMD typi‐
cally shows weakness around the hips of the patients. Thus, patients have difficulty in activities 
involving the lower extremities [23, 25]. Approximately 75% of muscle patients have muscle 
strength loss in the proximal limb of the extremity, 20% in the facioscapulohumeral, and 4% in 
the scapuloperoneal part of the body [26, 27]. However, in acquired diseases (such as inflam‐
matory myopathy), a loss of strength occurs subacutely. Some neuromuscular diseases affect 
specific muscles. FSHMD should be considered if there is asymmetric loss of strength in the 
muscles around the scapula, humerus, facial, and mimic muscles. Myotonic dystrophy (MD) 
should primarily be considered if there is involvement of the frontal and facial muscles, as well 
as the sternocleidomastoid muscle and the distal (especially tibialis anterior) muscles [26].
In CMT disease, in which foot and ankle problems and especially muscle weakness are com‐
monly seen, weakness typically begins in the intrinsic muscles of the foot and follows the per‐
oneus brevis and longus, tibialis anterior, extensor digitorum longus, and extensor hallucis 
longus muscles. This weakness pattern causes the muscle imbalance; while the plantar flex‐
ors remain relatively strong, the dorsiflexors weaken and consequently leads to the contrac‐
tion of the Achilles tendon. As a secondary to this muscle imbalance, together with calcaneus 
inversion, forefoot adduction, and claw toe, pes cavus deformity develops typically in CMT 
disease [28, 29]. Also, symptoms such as drop head, ptosis, dysphagia, and dysarthria can be 
seen in oculopharyngeal muscular dystrophy [18]. In patients with peripheral neuropathy, 
however, the loss of muscle strength has been shown to be more prominent in the foot dorsi‐
flexors, knee extensors, and hip flexor muscles [30].
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2.2. Postural control and balance problems
The strength necessary for the movement of the extremities is generated, collected, and trans‐
ferred to the upper extremity from the lower extremity by the postural control. Thus, the 
segments from the proximal to distal that are independent of each other operate in a specific 
interaction and concordance during functional activities [31].
The efferent system is composed of the structures necessary for postural control including 
vestibular, visual, and somatosensory inputs. The somatosensory input disorders can disrupt 
the postural control and lead to falls in neuromuscular diseases, which causes various condi‐
tions such as the weakness of the proximal or distal extremity (like patients with myopathy), 
axial weakness (myositis or amyotrophic lateral sclerosis), stiffness (myotonia), slow muscle 
contraction (nemaline myopathy), intermittently varying weakness (myasthenia gravis), sen‐
sory polyneuropathic end‐effector proprioceptive (myasthenia gravis), and sensory polyneu‐
ropathy resulting in proprioceptive insufficiency [32–34]. While the efferent system is also 
necessary to maintain a similar upright stabilization, it provides effective postural correction 
after perturbations during posture. The inadequacy of the efferent system can disrupt balance 
control and cause falls [35].
One of the problems that threaten postural control in neuromuscular diseases is the progres‐
sive nature of muscle weakness; the other is the inactivity due to the loss of ambulation fol‐
lowing the progression. In both cases, spinal stabilization is affected due to the motor and 
postural reasons, leading to spinal problems. In cases where the ambulation continues despite 
the decrease in muscular strength, many postural problems such as lordosis, kyphosis, sco‐
liosis, and wing scapula are observed due to the increase in the compensatory responses in 
the body [32, 36].
Scoliosis develops before the loss of ability to walk in 30% of muscle patients. The restriction 
of the paraspinal muscles causing the lordotic sitting posture in extension emerges as a result 
of locking of the posterior facets of the vertebral bone and the vertebral bones remaining flat‐
tened [37]. In addition, kyphotic sitting position is also preferred by patients as a result of the 
weakened paraspinal muscles. This kyphotic position prevents the locking of the posterior 
facets of the vertebral bones and causes the opening of the joint faces, vertebral rotation, and 
lateral curve formation. Finally, the functional scoliosis develops as a result of the inability of 
the vertebrae to resist to the gravity, the multifaceted adverse influencing of the posture, and 
difficulty in controlling this effect [38–40].
One of the major problems in the clinical postural control is pelvic obliquity. It affects the sit‐
ting balance and causes increased pressure on the lower ischial tuberosity, making the sitting 
position uncomfortable [41]. Also, the hip joint left on the higher side in the pelvic obliquity 
tends to be subluxated. Subluxation of the hips may also be observed secondary to progres‐
sive muscle weakness [42]. The increasing pelvic obliquity affects spinal stabilization. This 
condition affects the sitting balance of the patients and causes complaints of pain [43].
Hip movements are an important factor in correcting lateral balance; hence, proximal muscle 
weakness can disrupt the ability to balance during external shocks. Distal muscle weakness 
can lead to falls through different ways; the obstacles that do not look dangerous in normal 
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barrier‐free environments can cause the patients with dropped foot to stumble and lose bal‐
ance, increasing the risk of falls. In studies, it is emphasized that the rotations and movements 
of the ankles during standing is essential for maintaining and correcting the balance [44–47].
The wing scapula is observed in patients due to power loss in the shoulder girdle. Wing scap‐
ula adversely affects upper extremity functions [48]. Kyphosis and dropped head syndrome 
have been reported in some myopathies, particularly due to loss of strength in the neck exten‐
sor muscles. Patients with dropped head syndrome experience severe walking difficulty with 
loss of spinal smoothness [49, 50].
Proprioception plays an important role in stabilizing the body during both comfortable pos‐
ture and unexpected postural perturbations. Therefore, patients with peripheral neuropathy 
are unstable when their eyes are closed during standing. In addition, reflex responses to pos‐
tural perturbations are either delayed or decreased in amplitude or both [51–53].
In addition to the above‐mentioned findings that are directly related to postural control, pos‐
tural control plays an important role in many activities such as stair climbing, wheelchair 
activities, writing, bathing, makeup, shaving, eating, toilet needs, and in‐bed mobility [54, 55].
2.3. Atrophy
In this disease group that proceeds with progressive muscle weakness, the patients become 
more inactive and sedentary in time because the muscles are the active structures responsible 
for movement in the body. It is stated in the literature that atrophy develops between 14 and 
17% of muscle fiber after 72 h of immobilization [56]. Atrophy in muscular diseases develops 
later compared to peripheral nerve diseases. Selective atrophy of certain muscles may be asso‐
ciated with disease‐specific disorders [27].
2.4. Pseudohypertrophy
Pseudohypertrophy is a false hypertrophy seen in the muscle. The hypertrophic appearance 
of fibrils in the affected muscles results from the replacement of the fibrils by the fat and con‐
nective tissue. It does not cause a real increase in the strength of the muscle even though the 
muscle volume increases [57]. The hypertrophy in the muscle fibers that have not yet been 
lost is accompanied by the increase in the fat and connective tissue, and thus muscle mass 
increases. It is most commonly seen in the gastrocnemius‐soleus muscle group, occasionally 
in quadriceps, biceps brachii, and deltoid muscles. In addition, the presence of atrophic mus‐
cles around the muscles of the pseudohypertrophy may exaggerate this enlarged image [26].
2.5. Myotonia
Clinically, myotonia refers to any condition that prevents the relaxation of the muscles after 
contraction. The relaxation difficulty is evident in the first movement of the muscle after its 
resting position. Relaxation difficulty is reduced when the same movement is repeated after 
which the movements become easier. Although this is the only symptom in some diseases, in 
myotonic dystrophy it is associated with permanent muscle strength loss [26]. Myotonia seen 
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in MD and ALS is a factor affecting patients’ lives negatively in activities such as handshaking 
and jar opening.
2.6. Pain
Pain is an important problem in most of NMDs, but it is not typically a direct consequence 
of disease, and now researchers agree that chronic pain is a common symptom that can be 
seen in all forms of NMDs [58]. In a study on 511 NMPs involving DMD, BMD (myotonic 
musculoskeletal dystrophy (MMD), metabolic myopathy, FSHMD, and MG), Guy‐Coichard 
et al. evaluated the frequency, characteristics, and effects of pain; they found that the pain 
was moderate to severe in NMDs and emphasized that pain should be regularly assessed in 
this patient group [59]. Pain observed in neuromuscular diseases is the result of progressive 
muscle weakness, fatigue, ligament laxity or stretching, and abnormality of walking and 
posture [60]. In neuropathic conditions, however, pain‐causing mechanisms are neurogenic 
inflammation, abnormal involvement of the sympathetic nervous system, and the neuro‐
plasticity changes in the central nervous system. In a study aiming to determine the struc‐
ture and location of pain in muscle patients, 73% of the patients complained of pain, and 
27% of them were found to have severe pain [58]. In another study involving the evaluation 
of pain in 125 patients with neuromuscular disease from different groups, 73% complained 
of pain, 62% had chronic pain, and 15% had severe pain. The localization of the pain was 
reported to be spinal column in 81%, shoulder girdle in 54%, hip in 47%, and knee in 47%. 
In addition, 67% of these patients reported an increase in pain with walking and 68% with 
standing [60].
2.7. Contracture
Joint contractures, subluxations, and dislocations are common problems in NMDs [61, 62]. 
When the strength of the muscles around the same joint is different from each other, the joint 
tends to remain at a certain position, the corresponding muscle becomes shortened, and this 
position of the joint is fixed in time, resulting in the formation of contracture. The develop‐
ment of contracture occurs in patients with NMDs in time. The stiffness, which develops in 
the tendon and increases until contracture occurs, can be prevented or reduced by exercise or 
splints holding the joint in the opposite position [22, 26].
Flexion contracture is seen in hip joint with loss of strength of the hip extensor. The lumbar 
lordosis is increased so that the upright posture can be sustained and the loss of strength can 
be compensated. However, the progression of the weakness in the muscles of the pelvic girdle 
causes the knee flexion contracture to develop [62]. The increasingly apparent loss of strength 
in the gluteus maximus and quadriceps muscle leads to an excessively increased lordosis. 
As the patient tries to stabilize hips in the extension, lordosis becomes more pronounced. As 
the muscles weaken, the patient tries to increase stabilization by pulling the arms back and 
increasing the lordosis to pull the center of gravity behind the hip joint. Due to the loss of 
dorsiflexor muscle strength, plantar flexion contracture develops in the ankle joint, resulting 
in toe walking [48].
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2.8. Cardiopulmonary problems
Neuromuscular diseases cause respiratory problems mainly due to the inadequacy of the 
respiratory muscles, namely upper airway muscles (mouth and tongue muscles), external 
intercostal muscles, diaphragm, and abdominal muscles. The restrictive type of respiratory 
problem is observed in particular. Along with the involvement of the primary respiratory 
muscles in Becker MD and FSHMD, respiratory problems are encountered. The compliance 
of the chest wall is reduced, and then, there becomes a decrease in the total lung capacity. The 
disease may also cause kyphoscoliosis that increases the respiratory problem. Muscle fatigue 
in MG bears respiratory problems, whereas bulbar involvement in ALS causes increased 
secretion, inability to close glottis, and decreased respiratory control. In MM dystrophy and 
congenital myotonic dystrophy, a direct cardiac involvement is in the form of cardiomyopa‐
thies observed in addition to respiratory problems [63, 64]. Respiratory disturbances and car‐
diomyopathy may follow the development of scoliosis [65]. Respiratory muscle strength is 
insufficient in muscle patients. In particular, the maximal inspiratory (MIP) and expiratory 
(MEP) pressures are below normal values [66, 67].
The respiratory muscle weakness that emerges in the late stages of any neuromuscular dis‐
ease results in hypoventilation and hypercapnia. This causes restrictive pulmonary impair‐
ment and reduced exercise capacity [68, 69]. Moreover, during terminal stages of all diseases 
with muscle involvement, the weakness in the respiratory muscles restricts coughing. This 
problem may result in difficulty in swallowing and aspiration pneumonia. This in turn may 
cause the mechanical ventilator to be connected [69]. While cardiac involvement is mostly a 
result of respiratory involvement, it can be primarily seen as cardiac muscle involvement in 
some NMDs. In patients whose heart muscle is affected, the heart will have difficulty adapt‐
ing to changes in the body in the event of any increase in physical activity [70, 71].
The presence of cardiomyopathy resulting from a lack of dystrophin in the myocardium and 
cardiac Purkinje fibers affects the cardiopulmonary response to exercise. Myocardial dysfunc‐
tion remains silent due to decreased physical activity until the end of the disease process. 
The effect of cardiomyopathy and restrictive pulmonary disease on physical activity is much 
greater in NMDs with slower progression [1].
3. Activity problems in NMD
Although most neuromuscular disorders have progressive and clinically distinct features, 
the most important common feature is that they lead to functional problems and activity 
limitations at various levels [72]. The activity limitations due to the functional deficits vary 
depending on the localization of the affected region, on the type of the disease with secondary 
outcomes caused by loss of strength, and even on the patient [22]. The patients with muscle 
diseases usually go to the doctor with complaints such as difficulty in climbing stairs or a 
slope, getting up from the sitting position, walking, raising arms and reaching up, and wash‐
ing the head. The patients may also complain about numbness in feet and hands and not 
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being able to open eyes, and difficulty in swallowing. At the end of the natural progression of 
the disease, there may be a loss of strength in both the proximal and distal muscles and the 
inability to perform many activities such as wheelchair activities, writing, bathing, applying 
makeup, shaving, eating, toilet needs, and mobility within the bed [73].
Fatigue, cardiopulmonary effect, and exercise intolerance cause an increase in fat mass and 
contractures. It also causes a decrease in the efficient use of locomotion (such as reduced walk‐
ing space and more energy expenditure), a decreased motivation of the patient, a reduction in 
support of the social environment for activity, an increase in depression, and social barriers. 
These restrictions all result in a decline in physical activity performance in NMDs [1]. The 
progressive muscle weakness present in NMD directly affects the daily activities of the patient. 
Depending on the degree of muscle weakness in the proximal part of the body, patients may 
have difficulty in fine hand skills such as self‐care, dressing, and hygiene. The patients may also 
have difficulty in transfers requiring upper extremity support, ambulation activities, reaching 
to mouth due to the weakness of the distal muscle groups, bilateral use of cutlery, and nail 
clipping [74]. In a study involving 208 neuromuscular patients, Pieterse et al. have grouped the 
activities that the patients had difficulty under the following headings: (1) communication, (2) 
eating and drinking, (3) transfer, (4) walking and moving around, (5) transportation, (6) lifting 
and carrying, (7) fine hand skill, and (8) use of arms higher than shoulder level [75].
3.1. Fatigue
More than 60% of patients with NMD complain about severe fatigue along with muscle 
weakness and many other problems. Fatigue has a significant effect on exercise limitation 
and includes the physiological fatigue and the experienced fatigue [76]. The physiological 
fatigue is defined as an exercise‐dependent reduction in maximal voluntary muscle strength 
while the experienced fatigue is defined as difficulty in initiation and maintenance of volun‐
tary activities [77, 78]. The physiological fatigue is the one with both peripheral and central 
components, either muscular or related to limitation initiated in the central nervous system 
(CNS). Many mechanisms may cause this fatigue and exercise limitation [79]. In neuromus‐
cular diseases, there is the fatigue (peripheral fatigue) stemming from the local effects on the 
muscle function on one side, and there is the fatigue (central fatigue) arising from the level of 
CNS due to the feedback of the pathological condition in the peripheral nervous system on 
the other side. This type of fatigue protects the muscle from being damaged in the long term 
during the improperly set physical activities [77]. This symptom is perceived by patients as 
a different, abnormal, and feeling of being more tired than before the onset of disease [80]. 
In a study, which included the neuromuscular disease groups of HMSN, FSHMD, and MG, 
is indicated that severe fatigue is associated with functional impairment in daily life. The 
level of fatigue has been found to be significantly related to the muscular strength, the level 
of physical activity stated by the patient, sleep disorders, and pain. The fatigue level and the 
physical activity level are mostly associated with functional impairment in daily life [81].
3.2. Exercise intolerance and the impact on functional capacity
Exercise intolerance is a type of abnormally severe tiredness that develops with a certain 
movement in the muscle involved in that movement. In individuals with NMHD, several 
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factors such as loss of functional muscle tissue, unused muscles, injuries due to excessive 
use, cardiopulmonary involvement, contractures, decreased locomotion adequacy (decreased 
walking speed and increased energy expenditure), decreased patient motivation, less social 
participation for activity, increased depression, and increased social barriers lead to a decline 
in physical activity [1]. Three problems affecting functional capacity and determining the 
level of physical activity in NMD are often striking. These are muscle weakness, difficulty in 
exercising, and fatigue. These problems result in a decrease in physical activity and a seden‐
tary lifestyle [1]. Unfortunately, sedentary behavior increases exercise intolerance and causes 
a decrease in functional capacity in the subsequent periods, resulting in a low quality of life. 
The occurrence of fatigue is dependent on which of the energy‐producing metabolic path‐
ways were used during the activity. For example, if a patient develops exercise intolerance 
while walking but this patient is not uncomfortable while running fast, this should primar‐
ily suggest the impairment of lipid metabolism, which enables slow movements with type‐1 
muscle fibers. On the other hand, if the same complaint occurs in the arm muscles, for exam‐
ple, in an arm movement such as serial and rapid wiping, it should be primarily considered 
that the glycogen metabolism used by the type‐2 muscle fibers is defective in this case [82]. 
Individuals who have been diagnosed with NMD are more likely to live a sedentary life when 
compared to physically healthy people. A person with a lower level of physical activity will 
later have an increased body weight even with a normal diet. Increased body weight makes 
the patient more inactive, and this continues in a vicious cycle [83–85]. Therefore, when it is 
considered that all of the components required for exercise are relatively affected in NMDs, a 
reduction in exercise capacity in this disease group is inevitable.
3.3. Walking and mobility problems
Mobility is defined as the movement of the person around self and transition from one posi‐
tion to another in a safe manner; it is a function that should be carefully observed throughout 
the course of the disease in NMD [86]. NMDs progress with disorders limiting the patients’ 
mobility and their independence in daily life activities. The reason for this is that the pro‐
gressive weakness of the muscles affects the functional levels of the patients negatively after 
a while, leading to the defects in mobility activities such as standing up, walking, running, 
and stair climbing [87]. In the majority of NMDs, there is a chronic clinical course emerging 
slowly or progressing with a rapid decline in muscle strength that leads to impaired motor 
function. Neuromuscular patients suffer from difficulty in standing up from the ground as 
clinical signs of weakness of hip extensors, quadriceps, and trunk muscles. The increasingly 
apparent loss of power in the gluteus maximus and quadriceps muscles leads to an exces‐
sively increased lordosis. As the patient tries to stabilize hips in extension, lordosis becomes 
more pronounced. As the muscles weaken, the patient tries to increase stabilization by pulling 
the arms back and increasing the lordosis to pull the center of gravity behind the hip joint. 
To expand the area of support while walking, the patient walks like a duck (Trendelenburg 
gait) [88]. Fracture contracture is seen in hip joint with the loss of strength in hip extensor and 
the lumbar lordosis is increased so that the upright posture can be sustained and the loss of 
strength can be compensated. However, the progression of the loss of strength in the muscles 
of the pelvic girth causes the knee flexion contracture to develop [39]. The weakness of the 
hip flexor and the eccentric muscle reduces the length of stride. The weakness of the knee 
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extensor reduces the knee flexion moment in the midstance phase. Due to the weakness of 
dorsiflexion, plantar flexion contracture obstructs the stabilization of the foot during standing 
as well as the toe‐off during the swing phase [22].
Contractures may lead to postural disorders such as kyphoscoliosis and scoliosis, which 
can interfere with the continuation of sitting and lying activities, and as a result, pain. 
Furthermore, ortheses that help maintain the force, which reduce the development of con‐
tractures and deformities, and surgical medical procedures lead to additional disorders [89]. 
In the advanced stages of NMDs, various problems are faced such as wheelchair dependence, 
being confined to bed, difficulty in in‐bed transfers, inability to maintain mobility during 
climbing the stairs without holding to something like railing, not being able to stand up from 
the sitting position, and falling in and out of home [1]. This makes the patients dependent 
during their daily life activities.
3.4. Psychological and other problems
Even in normal individuals, being ill affects a person psychologically. In a condition such 
as that of neuromuscular patients where the disease is chronic and has many symptoms, 
this can make one feel more vulnerable. While some of the patients may cope with the prob‐
lems associated with the illness and adapt to the social life, some of them respond to these 
problems with limitations in school, social life, and daily activities. These restrictions mani‐
fest themselves as a decrease in independence and self‐confidence, limited participation, and 
social isolation, particularly in youngsters. For example, of two patients with muscular dis‐
eases with the same mobility level and the same severity of pain, one may continue to work 
while the other may quit or even show severe depression. In patients with NMDs, patients 
with increasing problems are severely affected, and with symptoms such as pain and fatigue, 
patients may not maintain their psychological well‐being [90].
4. Participation problems in NMD
It has been shown in the literature that mobility (transfers and walking), which is one of the 
parameters of social participation, housekeeping, community life, education, work, and lei‐
sure activities were affected in NMD [91]. Biomechanical problems present in NMDs lead to 
participation problems as a result of the increased energy expenditure levels and fatigue [92].
4.1. Falling and fear of falling
According to ICF, falling affects participation by deterioration of the affected body struc‐
ture and body functions [21]. Falling often has a complex form; it is defined as lying on the 
ground or at a lower level by accident, except conscious positional change for resting on seats, 
walls, or other objects, and is affected by multiple factors [93–96]. There are different descrip‐
tions, such as intrinsic and extrinsic factors, associated with the risk factors of falling [94, 
95]. These descriptions include age, duration of illness, presence of prior falls, fear of falling, 
the number of used medicines, use of antihypertensive medicine, reduction in mobility level, 
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and in‐home and out‐of‐home dangers [97, 98]. Also, risk factors include muscle weakness, 
the presence of falling history, gait abnormality, balance disorder, the use of assistive device, 
mobility limitation, visual disturbances, arthritis, depression, cognitive impairment/mental 
status changes, postural hypotension, vertigo/dizziness, incontinence, and chronic diseases 
[99, 100]. Prevention and reduction of falling have a positive effect on the patient's activity and 
participation level [101].
4.2. Environmental factors
Participation problems are encountered as a result of the interaction of environmental fac‐
tors experienced. Slippery floors, bed‐chair heights, poor lighting, unsuitable ancillary equip‐
ment, improper building designs, and broken or uneven pavements may be listed among the 
factors [93, 102].
4.3. Psychological factors
As the disabilities and difficulties start to be permanent in a patient's life, the patient may 
lose hope completely. Such people remove themselves from activities and social life, and face 
many problems including depression as a consequence [103, 104]. Hopelessness, the thought 
that no one can help them, is a common feeling for neuromuscular patients [105]. In a study of 
88 male patients with progressive musculoskeletal dystrophy, it was found that patients had 
problems in participating in private life and professional life and that more than half of the 
cases considered themselves to be socially isolated [104]. In his work to assess participation in 
myotonic dystrophies, Gagnon noted that the participation problems of these patients were 
about communication, personal care, and interpersonal relationships [106].
In NMD, the restriction of participation occurs in professional life, leisure activities, home, 
family, community, and social life [104]. Muscle weakness and reduced aerobic capacity 
may negatively affect participating in the professional life that requires long‐term physical 
activity. Deterioration of interpersonal interaction and relationships is another reason for the 
restriction of participation. Sometimes, this restriction can lead to extreme consequences such 
as no communication with people or not being able to eat or drink in public. Participation in 
the community and social life can also decrease due to depression and fatigue. The psycho‐
logical burden of having a degenerative and terminal illness affects the participation of the 
individual. The presence of each of these factors has significant adverse effects on the quality 
of life [107].
5. Assessment methods in rehabilitation of NMD
Nowadays, the key to planning a good rehabilitation program is to know the characteristics 
of the disease and the problems it will cause in the patient, and to evaluate the patient in 
detail in light of these features. In NMDs, evaluation is performed to monitor the progression 
of the disease, to determine the appropriate treatment methods, to investigate the efficacy 
of treatment methods, and to predict and prevent possible complications. Some evaluation 
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methods are used, in which the disorders of the body structure and function, and the limita‐
tions of activity and participation are evaluated. These methods include evaluation of respira‐
tory functions, muscle testing, normal joint movement, evaluation of flexibility, evaluation of 
motor functions and functional capacities, timed performance tests, functional posture, and 
gait analysis.
5.1. Assessment of muscle strength
Due to the diversity of neuromuscular diseases, it is crucial to determine the pattern or spatial 
distribution of weakness in the evaluation of muscular weakness to distinguish the etiology. 
It should be determined whether the loss of strength is general (e.g., bilateral, proximal, distal, 
or all) or localized [71, 108, 109]. The presence of the weakness predominantly in the proximal 
muscle groups or the dominance in the distal muscles, its presence on one or both sides of the 
body, and impairment in a single nerve or a group of nerves reflect the pattern of weakness 
[70]. In the case of huge weakness, it is determined whether the loss of function is proximal 
or distal, and which functional activities are limited by muscle weakness [108]. If the patient 
is having difficulty in standing up (around the hips) or combing the hair (around the shoul‐
ders), it indicates proximal muscle weakness, commonly observed among the weaknesses in 
myopathic diseases. If the weakness is pronounced around the hip, there are difficulties in 
getting up and down the stairs, standing up from the chair or toilet, or standing up from the 
ground or squatting position. If there is a weakness in the shoulder, there are many functional 
difficulties such as lifting heavy objects, reaching to and taking the objects on high shelves, 
brushing teeth, bathing, dressing, and combing the hair [108–110]. Generally speaking, proxi‐
mal muscle weakness seen in the form of a limb‐girdle pattern in the arms and legs and 
the muscle group of the shoulder and the hip circumference suggests a myopathic process 
(process affecting the muscles directly); the presence of distal weakness, however, primarily 
suggests prevalent polyneuropathy.
However, some myopathies cause distal weakness. This pattern usually cannot be diag‐
nosed and diagnostic errors are possible in relation to the neurogenic feature. The types of 
myopathic diseases with this atypical distal phenotype are known as distal myopathies and 
include MD and inclusion body myositis [108–110]. In less frequent cases of distal myopa‐
thies and neuropathies, patients complain of distal upper extremity weaknesses that cause 
difficulty in activities such as opening jars, buttoning, turning the key, and turning the door 
handle. Patients with distal lower‐limb muscle weakness complain about tripping over the 
pavement edges, having difficulty walking on uneven surfaces, or dragging feet during walk‐
ing. Patients experience difficulties standing on toes (m. gastrosoleus) or in activities involv‐
ing hands (intrinsic muscles) [108, 109].
Methods such as manual muscle testing, dynamometric evaluation, isokinetic (eccentric and 
concentric) evaluation, and surface electromyography (EMG) are used in the clinical evalua‐
tion of muscle strength, but manual muscle test (MMT) is the most commonly used method 
because of its easy application in clinical practice. Static and isometric contractions of the 
muscles are also measured with cable tensiometers or dynamometers. These measurements 
are superior methods because they provide numerical data in NMD, are objective, and reflect 
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changes in muscular strength [111]. However, manual muscle strength measurements remain 
valid today because of the low reliability of dynamometric measures in muscle groups that 
cannot complete their movements against the gravity or distal muscle groups [112, 113]. 
Nevertheless, the physiotherapist who will perform the muscle testing in NMD should be 
able to analyze whether the factors that limit muscle strength stem from weakness, loss of 
motor control, pain and/or fatigue, or whether the movements completed during manual 
muscle testing through compensations. Also, the physiotherapist should consider the time 
and quality of contraction, the range of motion (ROM) of the joint, and patient's ability to 
maintain contractions. For this reason, the evaluating physiotherapist should have performed 
a significant number of MMT‐related applications in neuromuscular diseases [22]. Another 
method is to find the maximum weight that a person can lift at once. For this purpose, iso‐
kinetic instruments have been developed that measure the maximum force at the specified 
speed in NMDs. These tools give information about both concentric and eccentric contraction. 
Studies have shown that it is reliable in good unipolar joints, especially elbows and knees. The 
use of these instruments is somewhat reliable because it is difficult to isolate the shoulder, 
wrist, and ankle muscles while measuring their strengths during particular movements. It is 
stated that it is more suitable to perform the force measurement using hand dynamometers 
providing better stabilization in these joints [114].
5.2. Assessment of range of motion and flexibility
Since there is the loss of muscle fibers in the intrinsic muscle tissue, contractures due to 
necrosis and fibrosis of the muscle fibers in NMDs, biomechanical analysis of the movement, 
and normal joint range of the motion and flexibility should be assessed for tracking the dis‐
ease progression. The range of motion of the joint is monitored objectively by goniometric 
measurements at regular intervals [115]. The active and passive normal range of the motion 
should certainly be assessed. The physiotherapist should maintain a record of the presence 
of limitation and whether the limitation is due to the muscle, the joint capsule, the tendon, 
or the pain and make a comparison of the agonist‐antagonist flexibility. The physiotherapist 
should consider this situation in the treatment program [22]. In muscle‐induced limitations, 
shortness of muscles should be particularly assessed, particularly since the shortness of hip 
and knee flexors, plantar flexors, lumbar extensors, latissimus dorsi, pectoral muscles, tensor 
fascia latae, and quadratus lumborum muscles are considered functional [116].
5.3. Assessment of motor function
There are some tests evaluating motor function in NMDs.”Motor Function Measurement 
(MFM)” is a scale with demonstrated validity and reliability developed to evaluate motor 
function in all NMDs. It was indicated that this is a scale, which evaluates the severity of 
motor impairment in the NMD group with good psychometric properties. It was indicated 
that, other scales, MFM is adapted to the severity of deficits at every level in patients who 
can or cannot walk and that it evaluates all of the head, trunk, lower, and upper extremities 
[117]. Some of these tests are specific to the disease, while others focus only on one area of the 
body. The “Spinal Muscle Atrophy Functional Motor Scale” was prepared for SMA patients 
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[118], the “Amyotrophic Lateral Sclerosis Functional Classification Scale” and the ALS score 
for patients with ALS [82], and the “Hammersmith Motor Skill Score” for patients with DMD 
[119]. Among the scales focusing only on one region/function of the body, Trunk Control Test 
and Trunk Impairment Scale are for the trunk [120, 121], the “Brooke Upper Extremity Scale” 
is for upper extremity [122], the “Vignos Lower Extremity Scale” is for lower extremity [123], 
the “North Star Ambulatory Assessment” is for ambulation [124] and the “Jebsen‐Taylor 
Hand Function Test” and “Activlim” are for the hand functions [125, 126].
5.4. Performance tests
The timed and controlled tests of the subsequent tests applied to the patient, evaluating the 
patient's ability to perform a specific activity in a specific time interval. These include some 
activities such as rolling from the supine to the prone position, rolling from the prone to the 
supine position, rising to the sitting position from the lying position, standing up without sit‐
ting, walking 10 m, climbing 10 steps up and down, and putting on a t‐shirt and taking it off 
[127]. The Minnesota, Purdue pegboard, nine‐hole peg test, and Jebsen hand skill tests were 
developed and are the most frequently used timed tests to assess hand functions [55]. There 
are no average values for the timed performance tests. The results are interpreted by compar‐
ing the clinical findings with the subsequent tests administered to the patient.
5.5. Fatigue
Two different methods are used in fatigue evaluations: electrophysiological tests and scales. 
Since electrophysiological tests are expensive, scales are more commonly used in clinics. 
The Multidimensional Fatigue Inventory (MFI) [128], the Fatigue Severity Scale [129], the 
Piper Fatigue Scale (PFS) [129, 130], the Short Fatigue Questionnaire (SFQ) [131], the Chalder 
Fatigue Scale (CSF) [132], Fatigue Impact Scale (FIS) [133], and Visual Analog Scale (VAS) are 
among the scales used for assessment of fatigue [134, 135]. While each of these tests has its 
advantages and disadvantages and is used in a large population of patients, none of the tests 
have been specifically developed for neuromuscular patients.
5.6. Respiratory function
The most commonly used evaluation methods in the clinic are the pulmonary function tests 
including spirometric measurements of “forced vital capacity (FVC)” and maximum inspi‐
ratory and expiratory pressures (MIP, MEP) [136]. Cardiopulmonary exercise tests are the 
evaluation of respiratory muscle strength, thoracic environment measurements, and assess‐
ment of respiratory frequency. In the literature, the recommendations on which respiratory 
evaluation should frequently be done in neuromuscular disease are given in Table 2 [137].
5.7. Assessment of cardiac functions
Symptoms of heart disease seen in NMDs depend on the severity of skeletal muscle insuf‐
ficiency and the severity and type of effect. The degree of neuromuscular insufficiency may 
modulate the symptoms of heart involvement and over time and may sometimes suppress 
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these symptoms [138]. The most commonly used screening test in clinic has two types: resting 
electrocardiography (ECG) and ambulatory ECG (Holter). Cardiac rhythm, intraventricular 
state, and ectopic beats can be evaluated noninvasively with ECG [139, 140]. In particular, 
cardiopulmonary exercise tests in individuals with severe neuromuscular disease generally 
show a decrease in maximal oxygen consumption, a decrease in pulmonary ventilation, a 
reduction in work capacity, and an elevation of resting heart rate. These findings reflect respi‐
ratory muscle involvement, cardiac decay, and poor physical fitness [69].
5.8. Pain
The characteristics of the pain should be recorded, such as localization, type, frequency, day‐
night difference, factors that increase or decrease the pain, change in pain with movement, 
and the presence of a response to a pain reliever. It should be established which of the causing 
factors of the pain are involved such as muscle imbalance, trigger points, joint tension, and 
muscle spasm. One‐dimensional and multidimensional scales are used to assess pain sever‐
ity. One‐dimensional scales are intended to measure pain intensity directly, and the patients 
make the assessment themselves. They are used especially in the evaluation of acute pain and 
in monitoring the efficacy of applied pain reliever. Among the one‐dimensional scales are 
the verbal category, numerical and visual comparison scale, and Burford Pain Thermometer 
[141–147]. Multidimensional scales are thought to be useful in certain cases to assess all 
aspects of pain in chronic pain [143]. These include the McGill Melzack Pain Questionnaire, 
the Dartmouth Pain Questionnaire, the West Haven‐Yale Multidimensional Pain Inventory, 
the Memorial Pain Assessment Card, the Wisconsin Brief Pain Inventory, the Pain Perception 
Profile, and the Behavioral Models [141–147].
5.9. Assessment of aerobic (functional) capacity
The purpose of evaluating functional capacity is to assess whether or not the maximal or 
submaximal activities can be performed in nonclinical settings. The ultimate standard to 
evaluate the person's aerobic exercise response is maximal increasing cardiopulmonary exer‐
cise test [148]. A suitable cardiopulmonary exercise test allows determining the underlying 
Test Frequency
History, physical examination Six monthly and in acute conditions
Lung function test (FVC, FEV1, VC—upright and supine) Six monthly and after acute conditions
MIP, MEP Six monthly and after acute conditions
Cough peak expiratory flow Six monthly and after acute conditions
Polysomnography At least yearly, symptom oriented and after acute 
conditions
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume; VC, vital capacity; MIP, maximum inspiratory 
pressure; MEP, maximum expiratory pressure.
Table 2. Respiratory follow‐up of patients with NMD [137].
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pathophysiological mechanisms. These mechanisms include broad assessment of the exercise 
response, the objective determination of the functional capacity and impairment, the mea‐
surement of the appropriate intensity required for long‐term exercise, the amount of fac‐
tors limiting exercise, and the contribution of various organ systems involved in exercise 
[149]. Functional capacity is assessed by maximal cardiopulmonary exercise tests, motorized 
treadmill, and stationary bicycle ergometer. However, submaximal tests are recommended 
in situations where maximal testing increases the patient's risk status and hinders his/her 
potential abilities, especially in individuals with significant risk for cardiovascular problems, 
and in cases where multiple cases are to be tested [148, 150]. The 6‐ or 12‐min walking test 
is a form of submaximal exercise assessment, finds extensive use in the field, is employed in 
pulmonary diseases and heart disorders, and evaluates the response to various treatment 
interventions especially pharmacological treatments and exercise training. The ability to walk 
at a specified distance is a quick, simple, and inexpensive way to evaluate physical func‐
tion. Walking is also a critical important component of the quality of life because it is highly 
necessary to accomplish the daily life activities and reflects patient's capacity [151, 152]. The 
validity study of the 2‐min walk test has been conducted in neuromuscular diseases, and it 
was put to use in recent years since its period of implementation is short and it does not cause 
fatigue [153, 154].
5.10. Assessment of functional mobility and falling
In clinical practice, the activity and participation problems are also encountered as a result of 
disorders seen in body structure and function in neuromuscular diseases according to ICF. 
However, walking emerges as a function related to all of ICF subparameters (body structure 
and functions, activity, participation, personal and environmental factors). In particular, two 
important conditions must be considered for mobility evaluation according to ICF: the capac‐
ity is the ability of an individual to perform a function or a task and what the individual is 
capable of doing in his/her environment is the performance [21].
Functional mobility, bed mobility, transfer, transfer grounds, gait, and wheelchair should be 
evaluated. The physiotherapist should assess the level of effort to initiate movement, weight 
transfer, postural alignment, motion timing and motion completion, patient balance, sup‐
port surface, walking assistance, and energy expenditure level [22]. The Rivearmed Mobility 
index is also used in mobility analysis [155]. Walking analysis is done by observational and 
three‐dimensional analysis methods. Some parameters and assessments may be used to ana‐
lyze the gait. These parameters include step‐length asymmetry, position of the ankle during 
heel strike, knee angle in heel strike, knee flexion angle in stance phase, single extremity 
support, state of foot and ankle in push phase, knee flexion in swing phase, body position, 
presence of Trendelenburg sign in frontal plane, knee cap in transverse plane, and foot angle 
and arm posture. The evaluation should be advanced to investigate possible causes in case of 
detection of a possible impairment in these standards [156]. For three‐dimensional analysis, 
computerized video cameras, passively reflected signal indicators, multicomponent power 
platforms, dynamic electromyographic analysis, and temporospatial gait analysis systems are 
used [154]. The timed‐up‐and‐go test, 30‐s chair‐stand test, the 4‐Stage Balance test [157–160], 
and risk analysis tools such as the Fall Risk Assessment Tool and STRATIFY (St. Thomas 
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Risk Assessment Tool) may be used for the evaluation of falling in neuromuscular diseases 
[161–163]. However, there is no specific cutoff value for NMDs in these tests.
5.11. Evaluation of activities of daily living (ADL)
Functional level deteriorates due to progressive muscle weakness in NMD, and dependence 
in ADL increases, while the tests such as Barthel, Katz, and Lawton are used for clinical evalu‐
ation of ADL in neurological patients [164]. FIM is the most preferred method for determining 
the levels of ADL in NMD. The advantage of FIM is that it has proven validity and reliability 
in evaluating many diseases and that it was found highly reliable by practitioners even when 
implemented by specialists with varying education and experience [165].
5.12. Sensory evaluation
In neuromuscular diseases with sensory involvement, especially in peripheral neuropathy, 
there is a need for frequent sensory evaluation. Surface sensations such as light touch (cotton), 
pain (sharp‐blunt test), and sense of temperature (with hot‐cold) and deep sensations such as 
vibration sensation, pressure recognition, touch localization, joint position, and motion sense 
should be evaluated [166].
5.13. General health measurements
These measurement methods give a general profile of health such as well‐being, functions, 
social, and emotional health. The most commonly used assessments in NMD in this group are 
“Nottingham Health Profile (NSP)” and the Short Form SF‐36 Quality of Life Survey [167].
6. The aim and content of the rehabilitation program
Although there have been some promising studies recently, there is no known curative 
approach to NMD. Physiotherapy and rehabilitation programs are gaining importance to 
maintain muscle strength, functional capacity, and quality of life as long as possible and 
to keep the patient in social life [168]. The lack of therapeutic approaches that can curb the 
 progression of the disease in a large proportion of neuromuscular diseases increases 
the importance of preventive, supportive, compensatory, and rehabilitative approaches. 
The aim of physiotherapy rehabilitation approaches is to improve the quality of life of 
patients and their families. Applications in that direction are to delay muscle weakness or 
loss of strength, to prevent muscle shortness and distortion in joints, to prevent respiratory 
problems, to maintain the walking activity for as long as possible, to educate the family, to 
support and keep the function at different stages of the disease, and to increase functional 
capacity [169]. The rehabilitation program should include the protection of the functional 
level of the patient and the physical and psychological functions, increasing the physical 
and mental capacity of the patient, and slowing the progress of the disease symptoms. 
Patients have a significant number of clinical problems, so rehabilitation should be done 
with a multidisciplinary team.
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6.1. The characteristics of the physiotherapist present in the rehabilitation team of 
neuromuscular patients
The effectiveness of the rehabilitation program to be administered in NMDs depends on the abil‐
ity of physiotherapists to assess and analyze the main causes of the patient's problems [22]. As a 
prominent member of the rehabilitation team, the physiotherapists who will evaluate and imple‐
ment the rehabilitation in NMD should be specialized for this group of patients and should be 
able to individualize the rehabilitation program. The physiotherapist should be able to identify 
the needs of NMD and be able to individualize the treatment program based on needs. The phys‐
iotherapist should have knowledge about the pathophysiology of the disorders in the patient 
and about the progression of the disease. The physiotherapist should be able to serve in differ‐
ent settings (inpatient and outpatient clinics, at home, at home‐care facilities, and in workplace 
arrangements) and various age groups. The physiotherapist should be able to follow up the 
patient with the short/long‐span controls during the planning of research on NMD, the devel‐
opment and implementation of outcome measurements, the setting of treatment interventions, 
and the natural progression of the disease and should be able to document the process well [22].
The rehabilitation program should include the muscle strength preservation, an exercise pro‐
gram for the prevention of contractures, increasing in respiratory function, increasing the 
functional (aerobic) capacity, walking and balance training, fall prevention and the stages of 
deciding walking aids, nutrition expert support, psychosocial approach, vocational counsel‐
ing, and ergotherapy processes.
6.2. Preservation of muscle strength and prevention of contractures
Many international researchers agree on the use of exercise therapy in neuromuscular dis‐
eases. There are many physical and psychological benefits of exercise such as muscle strength 
preservation, prevention of contractures, increased flexibility, reduced energy expenditure, 
relieving fatigue, reducing pain, depression, social isolation and loneliness, ensuring the 
participation of the individual active life, sustaining mobility, and increasing the quality of 
life. However, the number of studies with a high level of evidence about type, intensity, fre‐
quency, and speed of the exercise is limited. When deciding on a possible exercise program, 
the pathophysiology, onset, severity and the progression of the disease, the age and sex of the 
patient, and the intensity and frequency of the exercise to be given should be considered [170]. 
In general, there is a consensus on the positive effects of mild to moderate exercise programs 
on muscular strength without causing significant muscle damage, particularly in the early 
stages of neuromuscular disease with moderate progress when the muscle strength was not 
severely affected [171]. Combined use of upper/lower extremity exercises with neck and body 
exercises is preferred in clinical practice due to the ability to spread force from strong muscles 
to weak muscles and relieve fatigue [172].
6.2.1. Stretching and normal range‐of‐motion exercises
Stretching and normal range‐of‐motion exercises can prevent the limitation of joint mobility that 
develops as secondary to the muscle weakness [170]. The static stretching, which is usually used 
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for treatment in NMDs, is performed by proper alignment of the joint and bringing the muscle 
to its maximum length along the joint during stabilization of the unmovement joints. When 
the movement reaches the end, the position is held for at least 10 s and repeated. Although 
healthy individuals are recommended to make one to two repetitions a day or three to seven 
repetitions per week regarding the frequency of stretching, there is no definite information for 
neuromuscular patients. Daily stretching exercises are recommended. It has been reported that 
ROM increases with stretching frequency and the improvement was maintained for 4 weeks 
after the exercise ends [173]. Surveys show that a little 5‐min static stretching causes a change 
in the muscle‐tendon unit [174]. Resting splints can be used during sleep to prevent contrac‐
tures. When bed confinement has developed, lower extremities can be stretched using the body 
weight with standing table [175].
6.2.2. Strength training
Strength training can be done with resistance exercises. Resistance exercise training is one of the 
most effective ways to improve the functional capacity of the neuromuscular system. However, 
the potential benefits and risks of strength training in neuromuscular diseases are still a con‐
troversial subject in the literature. Progressive strengthening exercises are also commonly used 
to increase muscle strength in neuromuscular diseases [170]. Progressive strengthening exer‐
cises improve lean body mass, muscle protein mass, contractile strength, strength, and physical 
function. This improvement varies according to the rate of progression of the disease. There is 
a consensus in recent years about the benefits of mild to moderate intensity strength training 
(25–40% of maximum weight) on muscle strength without any deleterious effects, especially for 
slow‐progressing neuromuscular diseases [176]. Considering that the high‐intensity (50–70% 
of maximum weight) eccentric‐ or concentric‐type exercise programs would cause mechanical 
stress on muscle fibers and increase muscle weakness, they are not recommended for use on 
dystrophic types with rapid progression and membrane instability (such as Duchenne muscu‐
lar dystrophy) [170]. However, studies with opposite point of view also exist suggesting that 
high‐intensity training is beneficial with appropriate selection of patients [175]. However, no 
additional contribution to muscle strength and endurance was shown in a comparison of the 
maximum intensity weight training to the medium‐ and low‐intensity weight training [171].
Strengthening principles applied especially in healthy muscles should be used carefully here. 
The level of intensity and resistance, which is above the patient's muscle strength, strain the 
patient, and cause muscle fatigue, should be avoided. The patient should be recommended 
to do the exercises in parts during the day so as not to cause fatigue. It should be started 
with little or no resistance and few repetitions, and the frequency, duration, and resistance 
of the exercise should be monitored with monthly or tri‐monthly evaluations. The intensity 
and resistance of exercise should be revised if the patient experiences pain, muscle spasms, 
fasciculations, and excessive fatigue after exercises [177].
Electrical stimulation commonly used in the clinic for strengthening should also be used with 
caution in NMDs. Since all muscle fibers contract at the same time with electrical stimulation, 
it can increase degeneration in patients with low muscle fiber counts. For this reason, patients 
with muscle strength below three should use current types that will not cause fatigue [177].
Neuromuscular Diseases and Rehabilitation
http://dx.doi.org/10.5772/67722
195
6.2.3. In‐water exercises (aqua therapy)
In‐water exercises are the most appropriate exercise method for this group of patients. The 
water lift supports weakened muscles, permits functional movement, and in some cases can 
also be used as a resistance exercise. Pool exercises treat all muscle groups and maximize the 
aerobic capacity of the patient. It is particularly effective in a group of patients with limited 
energy levels. It is recommended in the literature to apply 45 min twice a week. Limitations of 
pool therapy are lack of accessibility and insurance payment [178].
6.3. Aerobic endurance training
Aerobic endurance training generates physiological responses that are different from strength 
training. Sufficient intensity and duration for aerobic training that involves the use of large 
muscle groups and will not cause fatigue is 50–85% of VO2max and 30 min. Aerobic training 
causes stimulation in the heart, the peripheral circulation, and the musculoskeletal system. As 
a result, circulation of more oxygen in the body leads to an increase in cardiac output, capil‐
lary density, and vascular transmission. For this benefit, aerobic exercises such as swimming, 
walking, and cycling can be performed, which put fewer burdens on the musculoskeletal 
system [179].
According to the American College of Sports Medicine guidelines, it is adequate to improve 
cardiorespiratory fitness for most aerobic training when an optimal frequency of 70–85% 
of maximum heart rate and 60–80% of maximum oxygen consumption are combined with 
an optimal frequency of 3–5 days per week [180]. A systematic review by Cup et al. sug‐
gests that an aerobic training at this intensity can be recommended to the NMD patients 
with a good functional level. In most of the studies included in the review, the cycling or 
treadmill exercises done at least three times a week and the use of approximately 70% of 
the heart rate reserve or the use of an estimated maximum heart rate are recommended. It 
is stated that the whole program lasting at least 10 weeks for both muscle strengthening and 
aerobic exercises and regular physical therapist supervision increases the effectiveness and 
improves the safety and suitability of the exercise [181]. However, in only 30% of all stud‐
ies involving muscle strengthening and aerobic exercises, training lasted for less than 10 
weeks, with an average of 5 weeks. In the literature, it is indicated that the aerobic exercise 
training in conjunction with muscle strengthening exercises is effective at evidence level 
of 2 or 3, especially in muscle diseases and neuromuscular patients with heterogeneous 
features [182].
6.4. Development of postural control
The activity of coming to sitting position from the supine position is an important activity 
of the body against the gravity and is one of the first stages of mobility. During this activity, 
which is very important for muscle patients also, the anterior trunk muscles contract concen‐
trically while the posterior trunk muscles contract eccentrically. The difficulty of the patient in 
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coming to the sitting position should bring into mind the possibility of encountering mobility 
problems and that the treatment should involve the precautions related to the trunk [121].
The equilibrium reactions have been tested in patients with isolated muscle weakness, and 
it was concluded that the muscle weakness is important. Although patients with distal leg 
weakness are particularly prone to stumble‐like stability disorders, the stability has been 
observed to decrease following the external perturbations of balance in proximal muscle weak‐
ness [32]. In previous studies, it has been shown that balance correction strategies assessed by 
dynamic posturography can vary depending on body parts where muscle weakness is present. 
Some muscle responses are sensitive to balance perturbations, especially in the sagittal (anterior‐
posterior) plane, while others are found to be sensitive to the frontal plane or a combination of 
these two planes. This reveals that the proximal and axial muscles (such as paraspinal or gluteus 
medius) are more frontal‐focused, the lower‐limb muscles are more sagittal‐focused sensitivity, 
and the knee muscles have the sensitive role in both directions in muscle response sensitivities 
following proximal to distal disturbances [183, 184]. Therefore, the patient maintains the bal‐
ance based on these sided sensitivities, and the question whether the patients with distal muscle 
weakness are more distressed in the sagittal plane and those with proximal lower extremity 
weakness are more distressed in the frontal plane should be answered. It is thought that this 
information can also help in the planning of therapeutic interventions. For example, patients 
with complete proximal weakness are unstable in balance correction strategies associated with 
the frontal plane; these patients will need a different intervention than those with complete dis‐
tal weakness and possibly unstable in strategies associated with the sagittal plane [185].
6.5. Increasing respiratory capacity
If there is a coughing weakness in the patient, airway cleaning techniques such as air stacking 
(glossopharyngeal breathing), mechanical, and manual coughing should be applied as soon 
as possible [186]. Increasing the pulmonary capacity, breathing exercises, diaphragm breath‐
ing exercises, and thoracic expansion exercises aim to maximize the expansion of the patients’ 
lungs and should be taught to the patient.
Pulmonary expansion therapy and maximal insufflation therapy (mask or mechanically 
assisted hyperinsufflation) increase the forced inspiratory vital capacity. It is reported in the 
literature that maximum insufflation therapy is important in increasing peak cough flow for 
neuromuscular patients with vital capacities less than 1500 mL [187]. Manually supported 
coughing techniques should be continued for maximum expansion. Secretion mobilization 
can also be provided by a positive expiratory pressure device. With a positive expiratory 
pressure device, patients breathe freely and breathe against a moderate resistance; air pres‐
sure activates secretions, preventing atelectasis. Traditional chest physiotherapy techniques 
used for airway cleaning should be taught to this patient population. This involves taking 
the patient to different positions, then clapping on the chest wall, vibrating, and coughing. 
However, it should be taken into account that Trendelenburg, lateral recumbent, and prone 
positions are difficult to tolerate in NMDs [186].
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6.5.1. Mechanical insufflation‐exsufflation (assisted coughing device)
The assisted coughing device operates according to the principle of vacuum cleaning. 
Cleansing of strong expiratory flow and secretions is achieved without tracheostomy by apply‐
ing negative pressure after maximal insufflation with a positive pressure of the oronasal mask. 
It is also known to be more effective than aspiration catheters in tracheostomized patients. 
The use of a peak cough flow below 160 L/min in NMDs is found appropriate. However, in 
recent publications, a cough flow of at least 300 L/min was used to initiate maximum assisted 
mechanical cough assistance [187–189]. The assisted coughing device produces an airflow of 
approximately 10 L/s with pressures between ‐40 cm HO
2
 and 40 cm HO
2
. It is a very vital 
and efficient device to use in patients using a mechanical ventilator and has reduced cough‐
ing ability [190]. Noninvasive mechanical ventilation devices are employed in later stages of 
NMDs. Indications for noninvasive mechanical ventilation are shown in Table 3.
6.6. Reduction of pain
The mechanism of pain has not been identified in detail in neuromuscular patients. For this 
reason, the physiotherapist should choose the appropriate treatment modality based on the 
pain source he/she has identified. From among the physiotherapy techniques, ultrasound, 
TENS, hot/cold application, and massage may be used but there are very few studies on the 
effectiveness of these techniques. There are even contradictory results regarding the increased 
muscle destruction of the ultrasound and hot application. Physiotherapists should be so 
cautious in their use. It is thought that TENS is preferred because it uses different ways of 
 inhibiting pain.
In the loss of muscle strength, joint pain can often be associated with improper alignment or 
excessive stretching of the joint capsule. Pain relief is possible with proper alignment of the 
joint and removal of excessive tension. However, since the weakness of each NMD patient is 
seen in different forms, it should be analyzed well before choosing the appropriate treatment. 
External support such as splints can be used when muscle weakness makes self‐stabilization 
impossible. An external shoulder splint may be utilized for the shoulder pain resulting from 
shoulder subluxation while an abdominal mattress may be preferred for back pain due to the 
excessive weakening of the abdominal muscles [22].
Shoulder pain may arise due to the single‐point cane, which NMD patients often prefer 
for cosmetic reasons. In this case, a four‐point walker may be used if the patient's energy 
• Chronic daytime hypercapnia with PaCO
2
 ≥ 45 mmHg
• Nocturnal hypercapnia with PaCO
2
 ≥ 50 mmHg
• Daytime normocapnia with a rise in PTcCO
2
 of ≥ 10 mmHg during the night
• A rapid, significant reduction in VC
• MIP <50 H
2
O cm or 60% and FVC <40%
Abbreviations: PaCO
2
, partial pressure of carbon dioxide (CO
2
) in the blood; PTcCO
2
, transcutaneous carbon dioxide; VC, 
vital capacity; MIP, maximum inspiratory pressure; FVC, forced vital capacity.
Table 3. Indications for noninvasive ventilation in neuromuscular diseases [137].
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expenditure level is not increased [154]. If the size of the four‐point walker is not suitable 
for the patient and the patient bends forward, this may be a possible reason for back pain. If 
the patient has a lack of postural control and the arms carry the whole load when the walker 
is used, this may be considered as a possible cause of pain in the upper extremity. If the 
patient's upper extremity strength is unable to carry the weight of the walker and the patient 
has upper extremity and back pain, then the arm‐assisted wheeled walker can be used to 
reduce pain.
The shoulder pain that occurs in patients using wheelchairs may be due to the improperly 
positioned inadequate arm support, which prevents the alignment of the humerus in the gle‐
nohumeral joint, while the hip and back pain may be caused by improper knee‐hip level and 
foot support. Wheelchair cushions, unsuitable pillows, and the bed should be considered as 
possible reasons for pain. The preference of a pressure distributing bed is also an important 
factor in reducing pain in bed dependence [22].
6.7. Walking and balance training
Mobility target should be determined according to the evaluation and the progression 
of the disease. Walking training should include endurance training, teaching the use of 
walking aids, orthotic approach and fall prevention, learning safe‐fall techniques, teach‐
ing how to stand up after falling, and teaching energy conservation techniques. In NMDs, 
the level of energy expenditure during walking increases [191]. For this reason, physio‐
therapists should choose the most appropriate aerobic exercise for the patient; the disease 
and exercise tolerance should be closely monitored. Physiotherapists should evaluate and 
recommend ambulatory assistive devices, transfer supports, and orthoses for improved 
walking, energy conservation, and safety if the patient develops weakness. However, the 
use of wrong assistive devices may alter the patient's optimal gait pattern and may pre‐
vent gait function or cause new problems in the patient. It has been shown that walking 
aids affect stability in a negative way in a group of studies in the literature. The reason for 
stability to be affected is that the upper‐ and lower‐extremity balance reactions, normally 
used to protect against falls and protective, are restricted by the walking aid [192]. There 
is also the problem of lower‐extremity tripping over the mobility aid. It is stated that the 
reciprocal movements necessary to use the walking aid in these situations are difficult to 
achieve. Choosing the right walking aid, using the right size, and training with the walk‐
ing aid can reduce the risk of falling [193]. Walking aids prevent falls when used safely; it 
should be kept in mind that they may be the most important reason for falling if misused 
[154]. When the falling story is evaluated, the frequency of falls, during which activity the 
fall occurred, the balance, sense, proprioception, the characteristics of the fall area, and 
the home environment should be evaluated. Balance and proprioception training should 
be given as a result of these evaluations. Recommendations for orthosis can be made by a 
physiotherapist, an orthotist, or a doctor. When orthosis advice is given, the desired func‐
tion, weight, and device tolerance should be considered, and a lightweight material should 
be used. The articulated orthoses may be granted if the patient has muscular strength to 
control the dynamic orthosis, fixed orthoses may be given if not. Walking training should 
be provided with the orthosis given [22].
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6.8. Training for the activities of daily living and adaptive approach
It has been shown that there is a negative correlation between manual muscle test results 
and FIM results in studies performed [194]. The manual muscle test score of 3 is a critical 
threshold value. The average muscle strength value being 3 is an important indicator that the 
patient is dependent/independent in the activities of daily living or a candidate for depen‐
dence [195]. Weakness in the upper extremities causes patients to lose their independence in 
basic activities of daily living such as dressing, nutrition, and personal hygiene. In addition, 
muscle weakness around the shoulder in diseases with more pronounced proximal muscle 
weakness causes difficulty in performing activities such as shaving, makeup, and weight 
lifting; distal muscle weakness causes difficulty in gripping and increases the functional defi‐
ciencies of patients in activities such as writing, turning the faucet on/off, and unlocking the 
door with the key [127]. It has been found that the activities indicated by the patients as the 
most challenging are climbing stairs (72%), taking along walk (40%), and getting on or off 
the bus (18%) [195].
To be able to perform the activities of daily living independently, the functional capacity of 
the individual and the environmental conditions necessary to carry out the activity should be 
able to match fully with each other. When there is a discrepancy between these two param‐
eters, problems arise which affect the quality of life of the person negatively. These problems 
can be solved by increasing the functional capacity of the individual, reducing environmental 
demands, and adapting the environment to the individual [196]. For example, if a person 
needs to pick up any item at the top shelf, he/she should be able to lift his/her arms over his/
her shoulder. If he/she cannot lift his/her arms, he/she cannot be considered completely inde‐
pendent of this activity. This problem can be solved by strengthening the shoulder muscles 
to allow the arms to be raised above the head, or by lowering the height of the shelf with 
a manually adjustable cabinet to the level at which the patient can lift his/her arms [195]. 
Neuromuscular patients need different aids at various periods of the disease to be able to 
perform their daily life activities independently as the disease progresses. Assistive devices 
include tools designed or modified to increase the functional capacities of persons with dis‐
abilities that can be considered in a broad spectrum. This equipment can range from simple 
tools such as jar openers, pen holders, electronic environmental control systems, toilet lifts 
to prevent fatigue, handlebars, forks, and spoons with thickened stalk, and adjustable beds 
to complex technological tools. Parallel to the developments in technology, assistive devices 
are also renewed every day. As the complexity and technology increase, the costs of the assis‐
tive devices also increase, making it difficult for patients to obtain these devices. Appropriate 
devices prescribed to a neuromuscular patient increase the patient's quality of life [195, 197].
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